Neurol. praxi. 2022;23(2):108-112 | DOI: 10.36290/neu.2021.082

Treatable inherited metabolic disorders with extrapyramidal manifestation in children

doc. MUDr. Miriam Kolníková, PhD., MUDr. Dominika Kovárová, MUDr. Patrícia Balážová, MUDr. Silvia Radová
Klinika detskej neurológie LF UK a NÚDCH, Bratislava

Inherited metabolic disorders are often manifested by movement disorders that are more or less expressed in the clinical presentation. They can be hyperkinetic: dystonia, chorea, athetosis, myoclonus, tremor stereotypies or hypokinetic: hypokinetic-rigid syndrome. Diagnosis of these diseases is often very difficult, because of the fact that the same movement disorder can be caused by various diseases. To our current knowledge, more than two hundred inherited metabolic disorders associated with movement disorders have been registered so far. In half of these diseases two or more symptoms are present, the most common of which are ataxia and dystonia. Appropriate diagnostic approach, which requires an accurate description of movement disorder, is impor­tant for early diagnosis and treatment (type, age and character of onset, extent of onset) as well as other neurological and others symptoms, laboratory results, radiological findings, genetic testing. The essential goal is rapid detection of treatable disorders.

Keywords: inherited metabolic disorders, dystonia, chorea, athetosis, hypokinetic-rigid syndrome.

Received: September 27, 2021; Revised: October 18, 2021; Accepted: October 18, 2021; Prepublished online: October 18, 2021; Published: April 21, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolníková M, Kovárová D, Balážová P, Radová S. Treatable inherited metabolic disorders with extrapyramidal manifestation in children. Neurol. praxi. 2022;23(2):108-112. doi: 10.36290/neu.2021.082.
Download citation

References

  1. Aulická Š, Česká K, Ošlejšková H. Syndrom GLUT-1 deficience - expandující klinické spektrum léčitelného one­mocnění. Cesk Slov Neurol. 2018;114(2):171-173. Go to original source...
  2. Bzdúch V, Sýkora P, Behúlová D, et al. Glucose transporter type 1(GLUT-1) deficiency: Short communications. Bratislava medical journal. 2008;109(5):245.
  3. Cohen BH, Chinnery PF, Copeland WC. POLG-Related Disor­ders. In: Adam MP, Ardinger HH, Pagon RA, editors. Gene­Reviews®. Seattle, WA: University of Washington, Seattle 2010. Available at: https://www.ncbi.nlm.nih.gov/books/NBK26471/.
  4. Cordeiro D, Bullivant G, Siriwardena K, et al. Genetic landscape of pediatric movement disorders and management implications. Neurol Genet. 2018;4:e265. Go to original source... Go to PubMed...
  5. Ebrahimi-Fakhari D, Van Karnebeek C, Münchau A. Movement Disorders in Treatable Inborn Errors of Metabolism. Mov Disord. 2019;34(5):598-613. Go to original source... Go to PubMed...
  6. Eggink H, Kuiper A, Peall K, et al. Rare inborn errors of metabolism with movement disorders: a case study to evaluate the impact upon quality of life and adaptive functioning. Orphanet J Rare Dis. 2014;9:177. Go to original source... Go to PubMed...
  7. Ferreira C, Hoffmann G, Blau N. Clinical and biochemical footprints of inherited metabolic diseases. I. Movement disorders. Mol Genet Metab. 2019;127:28-30. Go to original source... Go to PubMed...
  8. Ferreira C, van Karnebeek C, Vockley J, et al. A proposed nosology of inborn errors of metabolism. Genet Med. 2019;21:102-106. Go to original source... Go to PubMed...
  9. Garcia-Cazorla A, Ortez C, Pérez-Dueñas B, et al. Hypokine­tic-rigid syndrome in children and inborn errors of metabo­lism. Eur J Paediatr Neurol. 2011;15:295-302. Go to original source... Go to PubMed...
  10. Gregory A, Hayflick SJ. Pantothenate kinase-associated neurodegeneration. In: Adam MP, Ardinger HH, Pagon RA, editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle, 2002. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1490/.
  11. Kuiper A, Eggink H, Tijssen MA, de Koning TJ. Neurometa­bolic disorders are treatable causes of dystonia. Rev Neurol (Paris). 2016;172(8-9):455-464. Go to original source... Go to PubMed...
  12. Ng J, Papandreou A, Heales S, et al. Monoamine neuro­transmitter disorders - clinical advances and future perspectives. Nat Rev Neurol. 2015;11:567-584. Go to original source...
  13. Ortigoza-Escobar JD. A Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting with Movements Disorders. Frontiers in Neurology. 2020;11:1353. Go to original source... Go to PubMed...
  14. Patterson M. Niemann-pick disease type C. In: Adam MP, Ardinger HH, Pagon RA, editors. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle, 2000. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1296/.
  15. Rattay T, Lindig T, Baets J, et al. FAHN/SPG35: a Narrow phenotypic spectrum across disease classifications. Brain. 2019;142:1561-1572. Go to original source... Go to PubMed...
  16. Sanger T, Chen D, Fehlings D, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord. 2010;25:1538-1549. Go to original source... Go to PubMed...
  17. Sedel F, Saudubray JM, Roze E, et al. Movement disorders and inborn errors of metabolism in adults: a diagnostic approach. J Inherit Metab Dis. 2008;31:308-318. Go to original source... Go to PubMed...
  18. Zschocke J, Hoffmann GF, Milupa AG. Vademecum metabolicum: Manual of metabolic paediatrics. Friedrichsdorf: Milupa 2004.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.